Assess whether pediatric studies are necessary or waivable (50bb3f)

Situation

A mid-size sponsor after a complete response letter cannot treat a literature paper the 505(b)(2) package leans on getting retracted as color commentary on CMC comparability package for a site change. 505(b)(2) development lead must close pediatric studies are necessary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Authorize Pediatric studies are necessary now; CMC comparability package for a site change already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted.
• Keep Waivable in force until CMC comparability package for a site change is completed after a literature paper the 505(b)(2) package leans on getting retracted for 505(b)(2) development lead.
• Treat CMC comparability package for a site change as Pediatric studies are necessary because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page pediatric studies are necessary turns on in CMC comparability package for a site change.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.